Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe page’s revision label in the footer changed from v3.6.4 to v3.6.5, reflecting a new build of the site. This update appears to affect only metadata and not study content or user tasks.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new Revision: v3.6.4 entry was added to the study record history. The previous Revision: v3.6.3 entry was removed.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe footer now shows Revision: v3.6.3 instead of v3.6.2, signaling a new site release. There are no changes to the study records or page navigation reflected by this update.SummaryDifference0.0%

- Check47 days agoChange DetectedThe revision badge on the page updated from v3.6.0 to v3.6.2, signaling a platform release. No study data or navigation elements appear to be changed.SummaryDifference0.0%

- Check61 days agoChange DetectedThe recruitment status changed to not actively recruiting participants, and the record history shows a new software revision (v3.6.0) with the prior revision (v3.5.5) removed.SummaryDifference0.2%

- Check69 days agoChange DetectedThe history now shows Revision: v3.5.5 as the latest entry, replacing the previous Revision: v3.5.4.SummaryDifference0.0%

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.